Rise in Diabetes around the Globe Has Raised the Demand for Insulin Biosimilars in the Recent Years

 

Insulin biosimilars are the latest technology introduced in the field of diabetes care. Type I and II diabetes, which are respectively known as juvenile and adult, are generally the most common diagnoses in the world today. A majority of these cases are attributed to excessive glucose absorption in the small intestines due to genetic background. This is further aggravated by insulin resistance resulting from the body's inability to appropriately respond to external stimuli. Insulin biosimilars is considered as a very useful supplementary therapy in the treatment of insulin resistance, particularly for children and obese adults. This is attributed to the fact that insulin may not be absorbed well through the small intestine as a consequence of genetic differences and insufficient insulin receptors in obese individuals.

Diabetes accounts for a significant percentage of morbidity and death. Thus, there is a great need for innovative and more effective treatments and methods to control blood glucose levels. The treatment of type I diabetes with insulin biosimilar products consists of the administration of a single dose throughout the day, followed by a single shot in the evening The global insulin biosimilar market is constantly evolving and being improved, thanks to the continuous investment of pharmaceutical companies from different parts of the globe. Several new insulin analogs have been developed specifically for patients with diabetes and the clinical trials conducted are continuously yielding positive results. Insulin biosimilar can also be used to treat Type II Diabetes

There are four active ingredients found in the majority of insulin biosimilar products. These are Glucomannan, lecithin, pectin, and rice bran oil. Based on their chemical compositions, these products are classified into four primary groups, with each group having different potential applications: Type I, II, III, or IV.